Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefadroxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.98 |
| ▸ | MEN1 | O00255 | 5/20 | 0.98 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.83 |
| ▸ | HPGD | P15428 | 3/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.83 |
| ▸ | BLM | P54132 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | HTR2B | P41595 | 1/20 | 0.83 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefadroxil SCHEMBL10945661 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL1821440 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL28094893 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL33620 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9807365 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL1821442 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL2221955 | 1.00 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL19704546 | 0.99 | MAPT (0.96) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL11589366 | 0.99 | MAPT (0.96) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL19123520 | 0.99 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 869 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111526873-B | For modulating microbial colonization substituted diphenylacetylenes of (2) | 生物曼迪克斯有限责任公司 | 2025-03-04 | — | — | CN | claimed |
| CN-111526873-A | Substituted tolanes for regulating microbial colonization | 生物曼迪克斯有限责任公司 | 2020-08-11 | — | — | CN | claimed |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2020-07-02 | — | — | US | claimed |
| EP-3658128-A1 | SUBSTITUTED TOLANS FOR THE MODULATION OF MICROBIAL COLONIZATION | Biomendics, LLC (US) | 2020-06-03 | — | — | EP | claimed |
| CN-111057071-A | Preparation method of cefalexin | 刘思思 | 2020-04-24 | — | — | CN | claimed |
| WO-2019023425-A1 | SUBSTITUTED TOLANS FOR THE MODULATION OF MICROBIAL COLONIZATION | BioMendics, LLC (US) | 2019-01-31 | — | — | WO | claimed |
| US-20170266199-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-21 | — | — | US | claimed |
| EP-3182974-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-06-28 | — | — | EP | claimed |
| EP-2754663-B1 | Process for the crystallisation of cefadroxil monohydrate | DSM SINOCHEM PHARM NL BV (NL) | 2016-10-12 | — | — | EP | claimed |
| US-20160279058-A1 | PROTEIN-BASED GEL DELIVERY SYSTEM | CUBIC CORPORATION | 2016-09-29 | — | — | US | claimed |
| EP-0169995-B1 | A HIGH YIELD PROCESS FOR PREPARING BETA-LACTAM ANTIBIOTICS HAVING A HIGH PURITY DEGREE | IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (IT) | 1993-04-14 | — | — | EP | claimed |
| US-5003064-A | Method for the preparation of monohydrate | BIOCHIMICA OPOS SPA (IT) | 1991-03-26 | — | — | US | claimed |
| US-4898938-A | Method for preparing crystalline cefadroxil monohydrate | RIFAR S.R.L. (IT) | 1990-02-06 | — | — | US | claimed |
| CN-1036768-A | 7-/D (-)-alpha-amino group-α-(to hydroxyphenyl) kharophen/-preparation method of 3-methyl-3-cephem-4-carboxylic acid-hydrate | OPOS BIOCHIMICA SPA (IT) | 1989-11-01 | — | — | CN | claimed |
| EP-0302145-A2 | Method for preparing crystalline cefadroxil monohydrate | RIFAR S.R.L. (IT) | 1989-02-08 | — | — | EP | claimed |
| US-4625021-A | High yield process for preparing beta-lactam antibiotics having a high purity degree | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A. (IT) | 1986-11-25 | — | — | US | claimed |
| EP-0169995-A2 | A high yield process for preparing beta-lactam antibiotics having a high purity degree | IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (IT) | 1986-02-05 | — | — | EP | claimed |
| EP-0019345-B1 | PROCESS FOR THE PREPARATION OF A (D-ALPHA-AMINO-(P-HYDROXYPHENYL)-ACETAMIDO) GROUP CONTAINING CEPHALOSPORANIC ACID DERIVATIVES | GIST-BROCADES N.V. (NL) | 1985-06-19 | — | — | EP | claimed |
| EP-0019345-A1 | Process for the preparation of a (D-alpha-amino-(p-hydroxyphenyl)-acetamido) group containing cephalosporanic acid derivatives | GIST-BROCADES N.V. (NL) | 1980-11-26 | — | — | EP | claimed |
| EP-0001133-A1 | Process for the preparation of 6- D-alpha-amino-(p-hydroxyphenyl)-acetamido penicillanic acid | GIST-BROCADES N.V. (NL) | 1979-03-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | MAPT 1894/4885HSD17B10 4016/4885KMT2A 3977/4885 |
| US-20170266199-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | RIPK1, RIPK2, RIPK3 | MAPT 2019/4885HSD17B10 3757/4885KMT2A 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.